Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders

Oded Shamriz; Shoshana Revel Vilk; Dana G. Wolf; Asaf Ta-Shma; Diana Averbuch; Michael Weintraub; Polina Stepensky

doi:10.1016/j.clim.2014.01.007

Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders

Oded Shamriz^*, Shoshana Revel Vilk, Dana G. Wolf, Asaf Ta-Shma, Diana Averbuch, Michael Weintraub, Polina Stepensky

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity.Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.

Original language	English
Pages (from-to)	79-83
Number of pages	5
Journal	Clinical Immunology
Volume	151
Issue number	2
DOIs	https://doi.org/10.1016/j.clim.2014.01.007
State	Published - Apr 2014
Externally published	Yes

Keywords

Epstein Barr virus
ITK deficiency
Primary immunodeficiency
Rituximab
Stem cell transplantation
X-linked lymphoproliferative

Access to Document

10.1016/j.clim.2014.01.007

Cite this

@article{4c8e8bf8cdf34a1abbc63ff7635f1683,

title = "Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders",

abstract = "X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity.Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.",

keywords = "Epstein Barr virus, ITK deficiency, Primary immunodeficiency, Rituximab, Stem cell transplantation, X-linked lymphoproliferative",

author = "Oded Shamriz and Vilk, {Shoshana Revel} and Wolf, {Dana G.} and Asaf Ta-Shma and Diana Averbuch and Michael Weintraub and Polina Stepensky",

year = "2014",

month = apr,

doi = "10.1016/j.clim.2014.01.007",

language = "אנגלית",

volume = "151",

pages = "79--83",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders

AU - Shamriz, Oded

AU - Vilk, Shoshana Revel

AU - Wolf, Dana G.

AU - Ta-Shma, Asaf

AU - Averbuch, Diana

AU - Weintraub, Michael

AU - Stepensky, Polina

PY - 2014/4

Y1 - 2014/4

N2 - X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity.Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.

AB - X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity.Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.

KW - Epstein Barr virus

KW - ITK deficiency

KW - Primary immunodeficiency

KW - Rituximab

KW - Stem cell transplantation

KW - X-linked lymphoproliferative

UR - http://www.scopus.com/inward/record.url?scp=84894502318&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2014.01.007

DO - 10.1016/j.clim.2014.01.007

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 24584040

AN - SCOPUS:84894502318

SN - 1521-6616

VL - 151

SP - 79

EP - 83

JO - Clinical Immunology

JF - Clinical Immunology

IS - 2

ER -

Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this